{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:56:17Z","timestamp":1773971777670,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022725","name":"National Institute of Biomedical Genomics","doi-asserted-by":"publisher","award":["60122"],"award-info":[{"award-number":["60122"]}],"id":[{"id":"10.13039\/100022725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008129","name":"University of Burdwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["BT\/PR20699\/MED\/30\/1748\/2016"],"award-info":[{"award-number":["BT\/PR20699\/MED\/30\/1748\/2016"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jbc.2025.111096","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T07:39:51Z","timestamp":1766389191000},"page":"111096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["TIM-3 inhibition enhances breast tumor progression and metastasis: A paradoxical immune checkpoint response"],"prefix":"10.1016","volume":"302","author":[{"given":"Barnali","family":"Dolui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banani","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3045-237X","authenticated-orcid":false,"given":"Arghya","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8974-0707","authenticated-orcid":false,"given":"Kartiki V.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0608-9267","authenticated-orcid":false,"given":"Anupam","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2025.111096_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.21147\/j.issn.1000-9604.2020.02.01","article-title":"Cancer burden and trends in China: a review and comparison with Japan and South Korea","volume":"32","author":"Sun","year":"2020","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.jbc.2025.111096_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fimmu.2015.00310","article-title":"Inhibitory receptors beyond t cell exhaustion","volume":"6","author":"Fuertes Marraco","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2025.111096_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jbc.2025.111096_bib4","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbc.2025.111096_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jbc.2025.111096_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jbc.2025.111096_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.jbc.2025.111096_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.798683","article-title":"An emerging role of TIM3 expression on T cells in chronic kidney inflammation","volume":"12","author":"Lu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2025.111096_bib9","first-page":"56","article-title":"The roles of exosomal immune checkpoint proteins in tumors","volume":"8","author":"Xing","year":"2021","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.jbc.2025.111096_bib10","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1136\/gutjnl-2014-307671","article-title":"Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages","volume":"64","author":"Yan","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jbc.2025.111096_bib11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2025.111096_bib12","first-page":"8018","article-title":"Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer","volume":"8","author":"Zhou","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.jbc.2025.111096_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3892\/mco.2017.1360","article-title":"T-cell immunoglobulin mucin-3 expression in invasive ductal breast carcinoma: clinicopathological correlations and association with tumor infiltration by cytotoxic lymphocytes","volume":"7","author":"Zhang","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.jbc.2025.111096_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4149\/neo_2017_112","article-title":"Down-regulated expression of Tim-3 promotes invasion and metastasis of colorectal cancer cells","volume":"64","author":"Sun","year":"2017","journal-title":"Neoplasma"},{"key":"10.1016\/j.jbc.2025.111096_bib15","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1038\/s41598-017-09484-8","article-title":"Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status","volume":"7","author":"Wu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2025.111096_bib16","first-page":"1157","article-title":"Expression of Tim-3 in breast cancer tissue promotes tumor progression","volume":"11","author":"Cheng","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.jbc.2025.111096_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502128","article-title":"TIM-3 expression in breast cancer","volume":"7","author":"Burugu","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jbc.2025.111096_bib18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4048\/jbc.2018.21.e61","article-title":"T-cell immunoglobulin mucin 3 expression on tumor infiltrating lymphocytes as a positive prognosticator in triple-negative breast cancer","volume":"21","author":"Byun","year":"2018","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.jbc.2025.111096_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3892\/ol.2022.13318","article-title":"Prognostic significance of the expression levels of T-cell immunoglobulin mucin-3 and its ligand galectin-9 for relapse-free survival in triple-negative breast cancer","volume":"23","author":"Yoshikawa","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jbc.2025.111096_bib28","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4049\/jimmunol.1302663","article-title":"T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases","volume":"192","author":"Clayton","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jbc.2025.111096_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm0631","article-title":"Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function","volume":"7","author":"Tang","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jbc.2025.111096_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd2710","article-title":"Tim-3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion","volume":"7","author":"Zhu","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jbc.2025.111096_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.750542","article-title":"Regulatory T cells: regulation of identity and function","volume":"12","author":"Grover","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2025.111096_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2025.111096_bib33","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/ni.2084","article-title":"Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation","volume":"12","author":"Beyer","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jbc.2025.111096_bib34","first-page":"3789","article-title":"The role of FOXP3 in human cancers","volume":"36","author":"Szylberg","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jbc.2025.111096_bib35","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis [published correction appears in Ann Oncol. 2021;32:1308.]","volume":"32","author":"Emens","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbc.2025.111096_bib36","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib clinical trial of sabatolimab, an Anti-TIM-3 antibody, alone and in combination with Spartalizumab, an Anti-PD-1 antibody, in advanced solid tumors [published correction appears in Clin cancer res. 2024;30:3957]","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2025.111096_bib37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/gutjnl-2021-325808","article-title":"Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases","volume":"72","author":"Sullivan","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jbc.2025.111096_bib38","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-18-2202","article-title":"Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment","volume":"25","author":"Tulotta","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2025.111096_bib39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jbc.2025.111096_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.774103","article-title":"mTOR-mediated regulation of immune responses in cancer and tumor microenvironment","volume":"12","author":"Mafi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2025.111096_bib41","doi-asserted-by":"crossref","first-page":"14029","DOI":"10.18632\/oncotarget.7373","article-title":"Involvement of calprotectin (S100A8\/A9) in molecular pathways associated with HNSCC","volume":"7","author":"Khammanivong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbc.2025.111096_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1187741","article-title":"The functions and regulatory pathways of S100A8\/A9 and its receptors in cancers","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jbc.2025.111096_bib43","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.3389\/fimmu.2019.03136","article-title":"Molecular mechanisms controlling Foxp3 expression in health and autoimmunity: from epigenetic to post-translational regulation","volume":"10","author":"Colamatteo","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2025.111096_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-021-01472-x","article-title":"Dual CRISPR interference and activation for targeted reactivation of X-linked endogenous FOXP3 in human breast cancer cells","volume":"21","author":"Cui","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jbc.2025.111096_bib45","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1158\/0008-5472.CAN-14-2108","article-title":"FOXP3 controls an miR-146\/NF-\u03baB negative feedback loop that inhibits apoptosis in breast cancer cells","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.111096_bib46","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cac2.12416","article-title":"Tumor microenvironment signaling and therapeutics in cancer progression","volume":"43","author":"Goenka","year":"2023","journal-title":"Cancer Commun. (Lond)."},{"key":"10.1016\/j.jbc.2025.111096_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1206539","article-title":"Regulation, targets and functions of CSK","volume":"11","author":"Zhu","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jbc.2025.111096_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24437-6","article-title":"Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma","volume":"12","author":"Kazama","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2025.111096_bib49","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jbc.2025.111096_bib50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/mt.2013.255","article-title":"Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor","volume":"22","author":"McGray","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jbc.2025.111096_bib51","article-title":"Mouse 4T1 breast tumor model","author":"Pulaski","year":"2001","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.jbc.2025.111096_bib52","first-page":"5294","article-title":"TIM-3 expression and its association with overall survival in primary osteosarcoma","volume":"18","author":"Pu","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jbc.2025.111096_bib53","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","article-title":"The PRIDE database at 20 years: 2025 update","volume":"53","author":"Perez-Riverol","year":"2025","journal-title":"Nucleic Acids Res."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825029485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825029485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:48:19Z","timestamp":1773967699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925825029485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0021925825029485"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2025.111096","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TIM-3 inhibition enhances breast tumor progression and metastasis: A paradoxical immune checkpoint response","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2025.111096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"111096"}}